Neuropathic pain models and outcome measures: a dual translational challenge

Sewell, Robert David Edmund

doi:10.21037/atm.2018.09.58

Cited by 14 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This sort of pain is a functional derangement of the pain pathway 156 and can occur through alterations in any step of signal processing. Neurotransmitters, neuromodulators, and their respective receptors on neurons can be altered by neuroimmune mediators in presence, absence, or quantity, altering synaptic connectivity and leading to decreased modulation of the ascending pain signal and/or aberrant signaling by peripheral nociceptors.…”

Section: Neuroplasticitymentioning

confidence: 99%

The Study of Pain in Rats and Mice

2019

View full text Add to dashboard Cite

Pain is a clinical syndrome arising from a variety of etiologies in a heterogeneous population, which makes successfully treating the individual patient difficult. Organizations and governments recognize the need for tailored and specific therapies, which drives pain research. This review summarizes the different types of pain assessments currently being used and the various rodent models that have been developed to recapitulate the human pain condition.

show abstract

Section: Neuroplasticitymentioning

confidence: 99%

The Study of Pain in Rats and Mice

2019

View full text Add to dashboard Cite

show abstract

“…Furthermore, preclinical models are limited for many reasons. For example, neuropathic pain that is induced does not consider the perceptive, emotional, or affective components of pain [124]. Additionally, nutritional treatments effective in mice may not translate to effective treatments in clinical models.…”

Section: Discussionmentioning

confidence: 99%

Nutritional Supplements for the Treatment of Neuropathic Pain

Abdelrahman

Hackshaw

2021

Biomedicines

View full text Add to dashboard Cite

Neuropathic pain affects 7–10% of the population and is often ineffectively and incompletely treated. Although the gold standard for treatment of neuropathic pain includes tricyclic antidepressants (TCAs), serotonin-noradrenaline reuptake inhibitors, and anticonvulsants, patients suffering from neuropathic pain are increasingly turning to nonpharmacologic treatments, including nutritional supplements for analgesia. So-called “nutraceuticals” have garnered significant interest among patients seeking to self-treat their neuropathic pain with readily available supplements. The supplements most often used by patients include vitamins such as vitamin B and vitamin D, trace minerals zinc and magnesium, and herbal remedies such as curcumin and St. John’s Wort. However, evidence surrounding the efficacy and mechanisms of these supplements in neuropathic pain is limited, and the scientific literature consists primarily of preclinical animal models, case studies, and small randomized controlled trials (RCTs). Further exploration into large randomized controlled trials is needed to fully inform patients and physicians on the utility of these supplements in neuropathic pain. In this review, we explore the basis behind using several nutritional supplements commonly used by patients with neuropathic pain seen in rheumatology clinics.

show abstract

“… 1 It is not possible to directly measure pain in animals, as we do not have access to their subjective experiences, consequently many methods have been developed that quantify “nocifensive” behaviors, which are defined as behavioral responses to painful stimuli. Most nociception assays depend on a quick motor withdrawal reflex in response to a brief mechanical or thermal stimulation, and this simple movement is relatively easy to define and recognize, 2 – 5 but such assays lack similarity to clinical pain. In mice, these assays are genetically poorly correlated with more clinically relevant chronic pain assays 6 , 7 and are more closely associated with startle and reactivity traits.…”

Section: Introductionmentioning

confidence: 99%

Machine learning-based automated phenotyping of inflammatory nocifensive behavior in mice

et al. 2020

View full text Add to dashboard Cite

The discovery and development of new and potentially nonaddictive pain therapeutics requires rapid, yet clinically relevant assays of nociception in preclinical models. A reliable and scalable automated scoring system for nocifensive behavior of mice in the formalin assay would dramatically lower the time and labor costs associated with experiments and reduce experimental variability. Here, we present a method that exploits machine learning techniques for video recordings that consists of three components: key point detection, per frame feature extraction using these key points, and classification of behavior using the GentleBoost algorithm. This approach to automation is flexible as different model classifiers or key points can be used with only small losses in accuracy. The adopted system identified the behavior of licking/biting of the hind paw with an accuracy that was comparable to a human observer (98% agreement) over 111 different short videos (total 284 min) at a resolution of 1 s. To test the system over longer experimental conditions, the responses of two inbred strains, C57BL/6NJ and C57BL/6J, were recorded over 90 min post formalin challenge. The automated system easily scored over 80 h of video and revealed strain differences in both response timing and amplitude. This machine learning scoring system provides the required accuracy, consistency, and ease of use that could make the formalin assay a feasible choice for large-scale genetic studies.

show abstract

Neuropathic pain models and outcome measures: a dual translational challenge

Cited by 14 publications

References 23 publications

The Study of Pain in Rats and Mice

The Study of Pain in Rats and Mice

Nutritional Supplements for the Treatment of Neuropathic Pain

Machine learning-based automated phenotyping of inflammatory nocifensive behavior in mice

Contact Info

Product

Resources

About